US Patent

US9079934 — Antisense nucleic acids

Composition of Matter · Assigned to Nippon Shinyaku Co Ltd · Expires 2034-04-03 · 8y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects an oligomer that causes skipping of the 53rd exon in the human dystrophin gene and a pharmaceutical composition that achieves this with high efficiency.

USPTO Abstract

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

Drugs covered by this patent

Patent Metadata

Patent number
US9079934
Jurisdiction
US
Classification
Composition of Matter
Expires
2034-04-03
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Nippon Shinyaku Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.